1. Home
  2. RYZ vs CAPR Comparison

RYZ vs CAPR Comparison

Compare RYZ & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ryerson Holding Corporation Common Stock

RYZ

Ryerson Holding Corporation Common Stock

N/A

Current Price

$28.55

Market Cap

1.5B

Sector

Industrials

ML Signal

N/A

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$4.32

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYZ
CAPR
Founded
1842
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
2010
2011

Fundamental Metrics

Financial Performance
Metric
RYZ
CAPR
Price
$28.55
$4.32
Analyst Decision
Hold
Strong Buy
Analyst Count
1
8
Target Price
N/A
$44.63
AVG Volume (30 Days)
482.7K
5.6M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
2.82%
N/A
EPS Growth
N/A
N/A
EPS
0.42
N/A
Revenue
$4,571,300,000.00
N/A
Revenue This Year
$75.79
N/A
Revenue Next Year
$2.17
$3.31
P/E Ratio
$68.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.34
$2.96
52 Week High
$32.00
$40.37

Technical Indicators

Market Signals
Indicator
RYZ
CAPR
Relative Strength Index (RSI) 52.83 16.61
Support Level $26.01 $4.23
Resistance Level $29.08 $6.54
Average True Range (ATR) 1.43 0.80
MACD -0.06 0.07
Stochastic Oscillator 50.07 7.90

Price Performance

Historical Comparison
RYZ
CAPR

About RYZ Ryerson Holding Corporation Common Stock

Ryerson Holding Corp provides a metals service center, and value-added processor and is a distributor of industrial metals with operations in the United States, Canada, and Mexico. In addition to its North American operations, it conducts processing and distribution operations in China. It carries a full line of products in stainless steel, aluminum, carbon steel, and alloy steels and a limited line of nickel and red metals in various shapes and forms. The company has one operating and reportable segment, metals service centers. It derives substantially all of its sales from the processing and distribution of met. Geographically, the majority revenue is generated from the United States.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: